Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

What this Trial Is About

This research aims to evaluate lung function, exercise capacity, quality of life, and immune responses in adults who have recovered from COVID-19 over a period of up to three years. It also studies the durability of antibody responses after COVID-19 vaccination and investigates immune protection by testing plasma from vaccinated groups in a laboratory model. Additionally, the study explores the immune responses generated by different COVID-19 vaccines in community participants and assesses booster doses for those with low antibody levels after initial vaccination with CoronaVac. Participants include adults who recovered from COVID-19 and community members receiving one of three COVID-19 vaccines. The study involves lung function tests, exercise assessments like the six-minute walk test, chest imaging, and health questionnaires at multiple time points up to 36 months after recovery or vaccination. A subgroup of participants with low antibody levels after two doses of CoronaVac will be randomly assigned to receive a third booster dose either of CoronaVac or BionTech vaccine to compare immune responses. Participants will provide blood samples and undergo lung function and exercise tests at 6, 12, 24, and 36 months. Health status is assessed through questionnaires and imaging scans. Blood samples are used to measure antibody levels and T cell responses. Researchers monitor how immune responses change over time and evaluate the protective effect of antibodies in laboratory models. The total study duration for participants can be up to three years, with ongoing assessments to understand long-term health and immunity after COVID-19 infection and vaccination.

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19